PDS Biotech Q1 FY26 net loss narrows to $7.3 million; R&D expenses drop to $3.5 million

PDS Biotechnology

PDS Biotechnology

PDSB

0.00
  • PDS Biotech posted a Q1 net loss of USD 7.3 million, narrowing from a loss of USD 8.5 million a year earlier; loss per share improved to USD 0.13 from USD 0.21.
  • Operating loss narrowed to USD 6.52 million from USD 9.11 million, as R&D expense fell to USD 3.46 million from USD 5.83 million.
  • Cash and cash equivalents totaled USD 21.7 million at March 31, down from USD 26.7 million at Dec. 31, while net interest expense increased to USD 0.8 million from USD 0.6 million.
  • VERSATILE-003 Phase 3 protocol was amended to add progression-free survival as an interim primary endpoint, aiming to support a potential accelerated approval pathway for PDS0101 in HPV16-positive recurrent or metastatic head and neck cancer.
  • PDS01ADC enrollment completed in metastatic colorectal cancer, with early NCI-led mCRPC data showing median PFS of 9.6 months in combination with docetaxel; CEO Frank Bedu-Addo said the company is working to restart enrollment in the amended VERSATILE-003 trial.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605130700PRIMZONEFULLFEED9718648) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.